tiprankstipranks
Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
PremiumThe FlyNeumora Therapeutics reports Q1 EPS (34c), consensus (34c)
3M ago
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
PremiumPress Releases
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
3M ago
Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
PremiumThe Fly
Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
3M ago
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
PremiumPress ReleasesNeumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
4M ago
Neumora Therapeutics price target raised to $31 from $24 at RBC Capital
PremiumThe Fly
Neumora Therapeutics price target raised to $31 from $24 at RBC Capital
5M ago
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PremiumPress Releases
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
5M ago
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
PremiumPress ReleasesNeumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
6M ago
The biopharmaceuticals stocks to own in 2024, according to BofA
PremiumThe Fly
The biopharmaceuticals stocks to own in 2024, according to BofA
7M ago
Neumora Therapeutics price target raised to $20 from $18 at BofA
PremiumThe Fly
Neumora Therapeutics price target raised to $20 from $18 at BofA
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100